Dr. McKay highlights the ArteraAI Prostate Test
May 10th 2023"It is unique given that in addition to providing prognostic information, it can serve as a marker to predict sensitivity to androgen deprivation therapy (ADT), which is the backbone of systemic therapy for men with prostate cancer," says Rana R. McKay, MD.
Monitoring, feedback, and financial incentives improve uptake of active surveillance
May 8th 2023"The study demonstrated that AS rate in the MUSIC cohort, which in 2014 had been lower than in the SEER cohort, increased rapidly, from approximately 20% in 2014 to nearly 50% in 2019, whereas the SEER cohort showed only a modest increase," writes Badar M. Mian, MD.
FDA panel recommends limiting potential approval of olaparib/abiraterone to frontline BRCA+ mCRPC
May 2nd 2023The indication is restricted from the indication in the FDA supplemental New Drug Application for olaparib/abiraterone, which is for the population at-large in the BRCA–mutation positive setting.
Study identifies disparities in prostate cancer screening for transgender women
April 18th 2023“There is a lack of information regarding the prevalence and implications of [prostate cancer] in transgender women, and this highlights the crucial need for further research into prevention, detection, and treatment," says Hayley Premo.
Rapid genetic testing model found feasible for patients with prostate cancer
March 31st 2023"In our sample, nearly 10% of patients [with prostate cancer] had a gene variant that made them eligible for effective new therapies, with faster results than traditional referral for genetic testing and counseling,” said Maria I. Carlo, MD.
The safety and oncologic benefits of transperineal vs transrectal MRI-guided prostate biopsy
March 27th 2023"These studies, taken together, offer important insight into the direction we should be heading in prostate cancer diagnosis: toward a targeted-only TP biopsy," write Tarik Benidir, MD, and Zeyad Schwen, MD.
Hormone therapy plus current treatments improves survival in prostate cancer
March 23rd 2023Darolutamide increased overall survival compared to placebo in the overall patient population and patients with high-volume, high-risk mHSPC as well as in patients with low-risk metastatic hormone-sensitive prostate cancer.